April 20, 2024
Market Now
Pharma Research Products’ W18b contract terminated
[DISCLOSURE] Pharma Research Products (214450) announced on Jan. 19 that it has canceled a 17.8 billion won (US$15.14 million) contract to export D+CELL.
“The contract was canceled because the contract was not able to be fulfilled due to poor sales as the other party’s major sales personnel left the company and its operation was suspended,” said the company.
(theinvestor@heraldcorp.com)
“The contract was canceled because the contract was not able to be fulfilled due to poor sales as the other party’s major sales personnel left the company and its operation was suspended,” said the company.
(theinvestor@heraldcorp.com)
